MSD’s sotatercept has become the first FDA-approved therapy for pulmonary arterial hypertension (PAH) that addresses the underlying mechanism behind the disease, rather than its symptoms. The first-in ...
The treatment of pulmonary arterial hypertension—once a lethal condition—has evolved considerably over the past few years as the number of therapeutic options available to treat this disease has ...
Investing.com - Jefferies reiterated a Buy rating and $230.00 price target on Insmed (NASDAQ:INSM) shares following positive trial data from a competitor in the inhaled prostacyclin class. The stock ...
Neuroinflammation, a fundamental pathological process characterized by sustained activation of glial cells in the central nervous system (CNS), is widely implicated in the development of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results